HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Lowers Price Target to $58

Benzinga · 1d ago
HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $64 to $58.